Pfizer (PFE)
(Delayed Data from NYSE)
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
Pre-Market: $29.12 +0.03 (0.10%) 9:16 AM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
Pre-Market: $29.12 +0.03 (0.10%) 9:16 AM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
Pfizer as the Bull of the Day and Mesa Air Group have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Pfizer as the Bull of the Day and Mesa Air Group have been highlighted as Zacks Bull and Bear of the Day.
Bull of the Day: Pfizer Inc. (PFE)
by Bryan Hayes
With a dividend yield of 3% and a top Zacks VGM score of 'A', it's not hard to see why PFE is a top stock pick.
Glaxo (GSK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Glaxo's (GSK) COVID-19 solutions, newer respiratory and HIV drugs are likely to have driven fourth-quarter sales. The performance of vaccines during Q4 remains to be seen.
Bristol-Myers (BMY) Q4 Earnings Meet Estimates, Sales Beat
by Zacks Equity Research
Bristol-Myers (BMY) earnings match estimates in the fourth quarter of 2021, while sales beat the same on the back of Eliquis and Opdivo.
Pharma Stock Roundup: MRK, LLY, ABBV Post Q4 Earnings, PFE Ends Vupanorsen Program
by Kinjel Shah
AbbVie (ABBV), Merck (MRK), Eli Lilly (LLY) and Novartis (NVS) report fourth-quarter results. Pfizer (PFE) ends vupanorsen development.
Sanofi (SNY) Q4 Earnings Beat, Vaccines Hurt Sales Growth
by Zacks Equity Research
Sanofi (SNY) beats fourth-quarter estimates for earnings but misses the same for sales. Dupixent drives sales growth, offsetting lower vaccine sales.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Is a Surprise Coming for Pfizer (PFE) This Earnings Season?
by Zacks Equity Research
Pfizer (PFE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Best Growth Stocks to Buy for February 4th
by Zacks Equity Research
CROX, PFE, and AAPL made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 4, 2022
The Zacks Analyst Blog Highlights: Hasbro Inc., Pfizer Inc., Twilio Inc., CDW Corp. and Annaly Capital Management Inc
by Zacks Equity Research
Hasbro Inc., Pfizer Inc., Twilio Inc., CDW Corp. and Annaly Capital Management Inc are highlighted in this Analyst Blog Article.
Eli Lilly (LLY) Q4 Earnings Miss, COVID Therapies Aid Sales
by Zacks Equity Research
Eli Lilly (LLY) misses earnings estimates in the fourth quarter while revenues beat the same. Stock down in pre-market trading.
Merck (MRK) Q4 Earnings & Sales Beat, COVID Drug Adds $952M
by Zacks Equity Research
Merck (MRK) beats Q4 estimates for earnings and sales. The company anticipates robust growth in revenues and income to continue in 2022.
Roche's (RHHBY) 2021 Earnings, Sales Grow on COVID-19 Tests
by Zacks Equity Research
Roche (RHHBY) performance in the fourth quarter and 2021 was encouraging, driven by demand for COVID-19 tests and recovery in pharma sales. However, sales are expected to slow down in 2022.
Incyte (INCY) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Jakafi sales are likely to have driven Incyte's (INCY) top-line in the fourth quarter.
Best Growth Stocks to Buy for February 3rd
by Zacks Equity Research
CROX, TOL, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 3, 2022
5 Corporate Bigwigs to Buy Ahead of Earnings Next Week
by Nalak Das
Five corporate bigwigs will report fourth-quarter 2021 earnings results next week. These are: HAS, PFE, TWLO, CDW and NLY.
Zacks.com featured highlights include: Pfizer, The Kroger Co., Archer-Daniels-Midland Co., HP Inc. and Jones Lang LaSalle Inc
by Zacks Equity Research
Pfizer, The Kroger Co., Archer-Daniels-Midland Co., HP Inc. and Jones Lang LaSalle Inc are highlighted in this Screen of the Week article.
Novo Nordisk's (NVO) Q4 Earnings and Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk's (NVO) earnings and revenues beat estimates in Q4. Sales are driven by growth in Diabetes and Obesity Care on higher GLP-1 revenues.
Is a Beat Likely for Pfizer (PFE) This Earnings Season?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis (alliance revenue), Xtandi and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the fourth quarter.
Is a Beat Likely for Amgen (AMGN) This Earnings Season?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Kyprolis, Repatha and others and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Novartis (NVS) Q4 Earnings & Sales Miss, Sandoz Review Ongoing
by Zacks Equity Research
Novartis (NVS) reports dismal results for the fourth quarter. Key brands maintain momentum but the generics business remains weak.
5 Cheap Dividend Growth Stocks to Bet Amid Volatility
by Sweta Killa
Pfizer (PFE), Kroger (KR), Archer-Daniels (ADM), HP Inc. (HPQ) and Jones Lang (JLL) seems compelling cheap picks amid volatility.
Best Growth Stocks to Buy for February 2nd
by Zacks Equity Research
PFE, TOL, and M made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 2, 2022
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $53.07, marking a +0.72% move from the previous day.
Moderna (MRNA) Up on Its COVID Vaccine's Receipt of Full FDA Nod
by Zacks Equity Research
The FDA grants full approval to Moderna's (MRNA) mRNA-based COVID-19 vaccine, Spikevax, for individuals aged 18 years and above. Shares up.